Merck & Co., Inc. (NYSE:MRK) Updates FY 2026 Earnings Guidance

Merck & Co., Inc. (NYSE:MRK) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.660-2.760 for the period, compared to the consensus estimate of 3.420. The company issued revenue guidance of $66.3 billion-$67.3 billion, compared to the consensus revenue estimate of $66.7 billion.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on MRK shares. Guggenheim upped their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Morgan Stanley boosted their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Scotiabank increased their target price on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. BMO Capital Markets raised their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, UBS Group lifted their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Thirteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $134.50.

Merck & Co., Inc. Stock Up 0.7%

Merck & Co., Inc. stock traded up $0.83 during trading hours on Tuesday, hitting $128.60. The company had a trading volume of 1,718,073 shares, compared to its average volume of 10,744,324. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm has a market capitalization of $317.63 billion, a P/E ratio of 36.31, a price-to-earnings-growth ratio of 5.17 and a beta of 0.19. The firm’s fifty day moving average is $123.28 and its 200-day moving average is $118.66.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same quarter last year, the business posted $2.13 EPS. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate, while its loss of $0.13 per share was narrower than the expected $0.26 loss. Revenue increased 5.1% year over year. Merck Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Keytruda remained the primary growth engine. Sales of its new injectable formulation reportedly exceeded Wall Street expectations by more than $200 million, reinforcing Merck’s oncology momentum. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion analyst consensus, supported by newer products and Keytruda demand. Merck posts better-than-expected second-quarter results on Keytruda strength
• Neutral Sentiment: Merck also highlighted regulatory and clinical milestones across its pipeline, including updates to its HIV program. These developments could support longer-term growth but do not materially change near-term earnings expectations. Merck Second-Quarter 2026 Financial Results
• Negative Sentiment: Merck cut its FY 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus estimate. The reduction reflects charges associated with the acquisition of cancer biotech Terns Pharmaceuticals, putting pressure on near-term profitability despite the revenue outlook. Merck cuts profit guidance due to deal charges

Institutional Investors Weigh In On Merck & Co., Inc.

Several large investors have recently made changes to their positions in the company. Brighton Jones LLC raised its holdings in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after buying an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after acquiring an additional 3,941 shares during the last quarter. Quattro Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $54,000. Alvarez & Marsal Private Wealth Partners LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $47,000. Finally, Sfam LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $68,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.